NCT00045123Unknown2 期
Phase IIB, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Efficacy of MPC-7869 in Delaying the Systemic Progression of Prostate Cancer in Patients With Intermediate to High Risk of Recurrence With Rising PSA Levels After Prostatectomy, Prostatectomy and Radiotherapy or Radiotherapy Alone for Localized Disease
适应症
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- Myrexis Inc.
- 试验地点
- 114
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. R-flurbiprofen may be effective in delaying the recurrence of localized prostate cancer.
PURPOSE: Randomized phase II trial to study the effectiveness of R-flurbiprofen in treating patients who have localized prostate cancer at risk of recurrence following radiation therapy and/or prostatectomy.
详细描述
OBJECTIVES:
- Determine the effect of R-flurbiprofen on time to systemic disease progression evaluated over a minimum of 3 years in patients with localized adenocarcinoma of the prostate with an intermediate or high risk of recurrence and rising prostate-specific antigen (PSA) levels after radiotherapy alone, prostatectomy alone, or both radiotherapy and prostatectomy.
- Determine the effect of this drug on the change in serum PSA levels over time prior to androgen-deprivation therapy (ADT) in these patients.
- Determine the effect of this drug on the time of initiation of ADT in these patients.
- Determine the effect of this drug on the number of patients requiring ADT.
- Determine the safety of this drug in these patients.
- Determine the population pharmacokinetics of R-flurbiprofen and bioinversion of R-ToS in this patient population.
- Determine the number of patients with systemic disease progression at the end of the study.
- Determine the time to clinical disease progression in patients treated with this drug.
- Determine the time to prostate cancer-related mortality and time to all cause mortality in patients treated with this drug.
OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to risk of recurrence based on Gleason score at diagnosis (5-7 vs 8-10). Patients are randomized to 1 of 3 treatment arms.
- Arm I: Patients receive oral low-dose R-flurbiprofen twice daily.
- Arm II: Patients receive oral high-dose R-flurbiprofen twice daily.
- Arm III: Patients receive oral placebo twice daily. In all arms, treatment continues for up to 5.5 years (66 months) in the absence of disease progression or unacceptable toxicity. Patients who demonstrate increased prostate-specific antigen without objective disease progression and require androgen-deprivation therapy (ADT) continue receiving R-flurbiprofen. Patients who develop local recurrence or systemic disease may withdraw from study and receive additional therapy off study.
PROJECTED ACCRUAL: Approximately 390 patients (130 per treatment arm) will be accrued for this study within 3 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed localized adenocarcinoma of the prostate (from a pre-operative core biopsy, surgical specimen, or post-therapy core biopsy)
- •Gleason score 5-10 at diagnosis (the highest score is used if multiple scores are available)
- •Must have undergone 1 of the following curative treatment strategies:
- •Radical prostatectomy
- •Not a candidate for radiotherapy
- •Radical prostatectomy followed by radiotherapy at the time of surgery or any time thereafter
- •Radiotherapy of the prostate and/or surrounding structures by external beam radiotherapy (EBRT), brachytherapy (BT), or a combination of EBRT and BT
- •Must have 3 consecutive rising prostate-specific antigen (PSA) measurements OR meets slope criteria
- •Biochemical failure, meeting 1 of the following criteria:
- •PSA at least 0.2 ng/mL post radical prostatectomy
- •PSA greater than 1.5 ng/mL after radiotherapy or appropriate calculated slope
- •Testosterone at least 100 ng/mL
- •No rise in PSA with concurrent clinically active prostatitis
- •No metastatic prostate cancer
- •PSA no greater than 20.0 ng/mL
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Performance status
- •Karnofsky 70-100%
- •Life expectancy
- •Not specified
- •Hematopoietic
- •WBC at least 2,500/mm^3
- •Platelet count at least 100,000/mm^3
- •Hemoglobin at least 10 g/dL
- •Bilirubin no greater than 1.5 mg/dL
- •AST or ALT no greater than 2 times upper limit of normal
- •Creatinine no greater than 2.0 mg/dL
- •Cardiovascular
- •No uncontrolled cardiac conditions
- •No New York Heart Association class III or IV heart disease
- •Gastrointestinal
- •No active ulcer disease diagnosed within the past 3 months
- •No upper gastrointestinal bleed requiring a transfusion within the past 3 years
- •No non-steroidal anti-inflammatory drug (NSAID)-associated ulcers within the past 5 years
- •No known hypersensitivity to NSAIDs, including COX-2-specific inhibitors (e.g., celecoxib or rofecoxib)
- •No other malignancy within the past 5 years except basal cell or squamous cell skin cancer
- •No active systemic infections
- •No other serious uncontrolled medical condition
- •No dementia or altered mental status
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy
- •No concurrent biologic therapy
- •Chemotherapy
- •More than 5 years since prior cytotoxic chemotherapy for other malignant disease
- •No prior cytotoxic chemotherapy for prostate cancer
- •No concurrent chemotherapy
- •Endocrine therapy
- •More than 9 months since prior androgen-deprivation therapy other than as cytoreductive therapy (neoadjuvantly or adjuvantly for less than 9 months) with the intent to cure
- 另有 22 项未显示
排除标准
- 未提供
研究者
研究点 (114)
Loading locations...
相似试验
已完成
2 期
Doxorubicin and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Soft Tissue SarcomaSarcomaNCT00052390Memorial Sloan Kettering Cancer Center
撤回
2 期
Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung CancerLung CancerNCT00006374Case Comprehensive Cancer Center
已完成
2 期
ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerFallopian Tube CancerPrimary Peritoneal Cavity CancerOvarian CancerNCT00014690AstraZeneca
已完成
2 期
CCI-779 in Treating Patients With Prostate CancerProstate CancerNCT00012142Jonsson Comprehensive Cancer Center
已完成
2 期
PNU-93914 in Treating Patients With Locally Advanced or Metastatic Cancer of the EsophagusEsophageal CancerNCT00016900Memorial Sloan Kettering Cancer Center